Table 4: Estimation of Chronic kidney disease prevalence among HIV seropositive participants; before and after HAART exposure.
| Parameter | 4v-MDRD | CKD-EPI | ||||
| HAART-naïve {n/N (%)} | HAART-exposed {n/N (%)} | P value | HAART-naïve {n/N (%)} | HAART-exposed {n/N (%)} | P value | |
| Stage 1 (≥ 90) | 123 (61.50) | 116 (58.00) | > 0.05 | 53 (26.50) | 59 (29.50) | > 0.05 |
| Stage 2 (60 to 89) | 58 (29.00) | 64 (32.00) | > 0.05 | 111 (55.50) | 108 (54.00) | 0.052 |
| Stage 3 (20 to 50) | 19 (9.50) | 19 (9.50) | > 0.05 | 33 (16.50) | 30 (15.00) | > 0.05 |
| Stage 4 (10 to 20) | 0 (0.00) | 1 (0.50) | 0.23 | 3 (1.50) | 1 (0.50) | 0.03 |
| Stage 5 (< 10) | 0 (0.00) | 0 (0.00) | - | 0 (0.00) | 2 (1.00) | 0.02 |
4v-MDRD - Four variable Modification of Diet in Renal Disease; CKD-EPI - Chronic Kidney Disease Epidemiology collaboration;
Grade of Severity of Renal dysfunction and it Glomerular Filtration Rate in ml/minute: Normal (stage 1) => 50,
Mild (stage 3) = 20-50, Moderate (stage 4) = 10-20, Severe (Stage 5) =< 10.
P value was calculated by Pearson's Chi square (χ2) with confidence interval (CI) of 95% and 1 degree of freedom (df).
P values less than 0.05 were considered statistically significant and are indicated in bold fonts.